Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M)

Background Advances in HIV-1 therapeutics have led to the development of a range of daily oral treatment regimens, which share similar high efficacy rates. Consequently, more emphasis is being placed upon the individual’s experience of treatment and impact on quality of life. The first long-acting i...

Full description

Saved in:

Bibliographic Details
Published in:	The patient : patient-centered outcomes research Vol. 14; no. 6; pp. 849 - 862
Main Authors:	Chounta, Vasiliki, Overton, Edgar T., Mills, Anthony, Swindells, Susan, Benn, Paul D., Vanveggel, Simon, van Solingen-Ristea, Rodica, Wang, Yuanyuan, Hudson, Krischan J., Shaefer, Mark S., Margolis, David A., Smith, Kimberly Y., Spreen, William R.
Format:	Journal Article
Language:	English
Published:	Cham Springer International Publishing 01.11.2021 Springer Nature B.V
Subjects:	Anti-HIV Agents - therapeutic use Antiretroviral drugs Clinical trials Drug dosages Drug therapy Health Administration Health Economics HIV HIV Infections - drug therapy HIV-1 Human immunodeficiency virus Humans Medicine Medicine & Public Health NCT NCT03299049 Original Original Research Article Patient Reported Outcome Measures Patient satisfaction Pharmacoeconomics and Health Outcomes Public Health Pyridones Quality of Life Quality of Life Research Questionnaires Rilpivirine - therapeutic use
ISSN:	1178-1653, 1178-1661, 1178-1661
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!